Neil Gunn

Roche Sequencing Solutions, Inc. engages in providing personalized healthcare by creating diagnostics and treatments tailored to individual genetic and disease profiles. The firm's solutions include NGS Oncology Assays, sample collection, nucleic acid extraction and library preparation. The company is headquartered in Pleasanton, CA.

IDbyDNA, Inc. operates as a precision medicine company that focuses on metagenomic approaches for infectious disease identification. It develops technologies to enable universal microorganism detection. The firm help doctors and scientists to detect any pathogen in any sample, thereby removing barriers for the adoption of metagenomics in clinical settings, ultimately leading to faster public health responses during infectious disease outbreaks. The company was founded by Martin G. Reese, Guochun Liao, Mark Yandell, and Robert Schlaberg in Noveber 2014 and is headquartered in San Mateo, CA.

Alveo Technologies, Inc. operates a pre-clinical stage medical diagnostics company that creates infectious disease diagnostic devices. The company was founded by Ron Chiarello, Michael A. Aicher, Lawrence M. Blatt and Sumita Pennathur in 2014 and is headquartered in Alameda, CA.

Rarecells USA, Inc. is a company dedicated to early cancer detection to save lives. The company is based in New York, NY. The company believes that accurate and early cancer detection has the potential to save millions of lives. Rarecells is developing a prostate cancer test and a multi-cancer test for early cancer diagnosis. The company is currently conducting three clinical studies to evaluate the performance of their dedicated iset-based assay. The company was founded in 2011 by Patrizia Paterlini-Bréchot, who has been the CEO since 2011.

Rarecells Diagnostics SAS is a French company passionate about saving lives by detecting and eliminating cancer at its start. The company is based in Paris, France and was founded by Patrizia Paterlini-Bréchot, who has been the CEO since incorporation. The company believes that accurate, early cancer detection has the potential to save millions of lives. Rarecells Diagnostics has developed the ISET blood filtration technology, which enables cell culture to generate xenograph of avatars. The company is currently conducting three clinical studies to evaluate the performance of their dedicated ISET-based assay to allow early detection of prostate cancer. The company is also developing a multi-cancer test for early cancer diagnosis and is working with researchers to propel care forward.

Roche Molecular Systems, Inc. develops and produces molecular-based diagnostic tests and automated testing platforms. It specializes in oncology, virology, microbiology and blood screening tests areas. The firm's customers include researchers, physicians, patients, hospitals, laboratories and blood banks. The company is headquartered in Pleasanton, CA.